INNOVATION IN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION: STIMULATOR OF SOLUBLE GYANYLATE CYCLASE - RIOCIGUAT
Pulmonary arterial hypertension (PAH) is a rare disease, diagnosed at a late stage with low functional class III or IV (WHO). PAH leads to severe right heart failure and ultimately, death. The modern researches aim at exploring the potential therapeutic targets, as at developing new drugs that can a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2015-12-01
|
| Series: | Евразийский Кардиологический Журнал |
| Online Access: | https://www.heartj.asia/jour/article/view/5650 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|